Track topics on Twitter Track topics that are important to you
- to evaluate the safety and PK of multiple-dose oral administration of S-707106 tablet in fed state in patients with type 2 diabetes mellitus
- to evaluate the safety and PK of multiple-dose oral co-administration of S-707106 and metformin in fed state in patients with type 2 diabetes mellitus
- to evaluate the effect of multiple doses of S-707106 on PK of metformin
- to evaluate the effect of multiple doses of metformin on PK of S-707106
Safety will be evaluated by monitoring of treatment-emergent adverse events (TEAEs), clinical laboratory evaluations, vital signs, 12-lead ECGs, 24-hour telemetry monitoring and physical exams.
Specific study withdrawal criteria during washout periods of metformin have been established for loss of glycemic control-i.e.-glucose monitoring.
PK assessment of monotherapy cohort versus add-on therapy.
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Type 2 Diabetes Mellitus
S-707106 tablet, Placebo, Metformin, S-707106 tablet + Metformin, Metformin, placebo + Metformin
Dennis Ruff, MD
Shionogi USA, Inc.
Published on BioPortfolio: 2014-08-27T03:12:31-0400
Single-dose, randomized, open-label, cross over study. The study will have an open-label, 3 period, 3 treatments, and randomized design. Each volunteer will receive a Metformin gum 2x250m...
This trial is conducted in Asia. The aim of this clinical trial is to investigate the bioequivalence of repaglinide and metformin combination tablet versus repaglinide and metformin as coa...
In this integrated, Phase I study, the safety, tolerability, food effect, and pharmacokinetic (PK) properties of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin X...
This is a bioequivalence study of two doses of the dapagliflozin/metformin XR tablet manufactured at two different plants.
To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg metformin (Glucophage Marketed in Can...
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.
Metformin use is restricted in patients with renal impairment due to potential excess systemic accumulation. This study evaluated the glycemic effects and safety of metformin delayed-release (Metformi...
Metformin is the first line management for patients with Type 2 diabetes mellitus. Metformin-induced lactic acidosis (MALA) is a severe side effect of metformin in high doses. However, there have no...
Metformin is a widely used first-line drug for treatment of type 2 diabetes. Despite its advantages, metformin has variable therapeutic effects, contraindications, and side effects. Here, for the very...
Although metformin is widely prescribed in diabetes, its use with associated cardiac dysfunction remains debatable. In the current study, we investigated the effect of metformin on coronary microvascu...
Metformin is recommended as the first-line treatment of type 2 diabetes mellitus. Despite its common use, few studies have been conducted to precisely measure the efficacy of metformin versus placebo ...
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.
A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
Products in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. (FDA Backgrounder, June 15, 1993, p2)